Senior Scientist
Earli
Senior Scientist
Earli
Biotech platform enabling early cancer detection
Earli tackles the #1 problem in the $100B cancer drug market: systemic toxicity. On-target/off-tumor effects force suboptimal dosing, reduced efficacy and sidelining some of the most potent drug classes such as cytokines. Earli’s BioAI approach flips this paradigm: Drugs are producedonly where needed—in the tumor,by the tumor,against the tumor. Cancer cells become their own drug factories, enabling localized immune activation, even in cold tumors.
This was enabled by three core innovations:
Together, these technologies create a new biological control layer, allowing tumors to self-identify and trigger their own targeted immune attack—achieving specificity beyond current targeted or IO therapies.
Earli plans to enter the clinic by mid-2027 with a Phase 1/2 lung cancer trial. The company is backed by a16z, Khosla, Perceptive, Alex Gorsky, Marc Benioff, Breyer, Emerson Collective, Sands Capital and others. The SAB includes Jim Allison (Nobel Laureate, MD Anderson), Bob Langer (Co-founder Moderna, MIT), Phil Greenberg (Co-founder Juno), Amy Abernethy (frm. Principal Deputy FDA Commissioner), Bill Hait (former J&J EVP Oncology R&D), and Alan Ashworth (President UCSF Cancer Center). The leadership team brings deep gene therapy, LNP, CMC and tech experience; CEOCyriac Roeding previously led a $250M (11x return) exit.
Who You Are
The Position
Earli Inc. is currently seeking a top caliber Senior Scientist, Bio AI to join our Synthetic Bioengineering team.
Your Primary Responsibilities
Your Required Experience, Knowledge and Skill
The base salary for this position is $205,000-$235,000 per year.
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
Earli develops a cancer diagnostic platform that uses synthetic biology to create Synthetic Bioclassifiers. These genetic constructs enter cells and, if a cell is cancerous, activate to make the cell produce a biomarker that is released into the bloodstream for detection. The system is programmable to distinguish cancerous from healthy cells, addressing the limits of traditional liquid biopsies by prompting cancer cells to reveal themselves. It plans to commercialize this platform through partnerships with healthcare providers and pharmaceutical companies, with Accenture as a strategic investor.
Explore more opportunities at Earli